Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 8/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.50 |
| ▸ | BAX | Q07812 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.47 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.47 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL888019 | 1.00 | LTA4H (0.57) | LTA4HTSHRNR1H2BAXMAOA | |
| SCHEMBL9422169 | 0.90 | PARP15 (0.42) | LTA4HTSHRNR1H2BAXMAOA | |
| SCHEMBL9654773 | 0.90 | PARP15 (0.42) | LTA4HTSHRNR1H2BAXMAOA | |
| SCHEMBL3085615 | 0.89 | FFAR1 (0.52) | LTA4HTSHRNR1H2BAXMAOA | |
| SCHEMBL21925450 | 0.87 | SRD5A2 (0.68) | PARP10SRD5A2 | |
| SCHEMBL9422165 | 0.86 | ALDH1A1 (0.54) | LTA4HTSHRGSTP1PARP10FFAR1 | |
| SCHEMBL3079739 | 0.84 | RELA (0.50) | SRD5A2 | |
| SCHEMBL3079740 | 0.84 | RELA (0.50) | SRD5A2 | |
| SCHEMBL3080310 | 0.82 | MAOB (0.61) | MAOACA1CA2GSTP1CA9 | |
| SCHEMBL11592340 | 0.82 | LTA4H (0.52) | LTA4HTSHRNR1H2BAXMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 276 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116789763-A | Permeable membrane polypeptide and application thereof in resisting colon cancer | 上海交通大学医学院 | 2023-09-22 | — | — | CN | claimed |
| CN-116731107-A | Membrane penetrating cyclic peptide and application thereof | 宁夏医科大学 | 2023-09-12 | — | — | CN | claimed |
| US-20070203138-A1 | Novel Compounds and Compositions as Cathepsin S Inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-08-30 | — | — | US | claimed |
| US-20070135386-A1 | Novel Compounds and Compositions as Cathepsin Inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-14 | — | — | US | claimed |
| US-7226921-B2 | Compounds and compositions as cathepsin S inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-05 | — | — | US | claimed |
| US-7196099-B2 | Compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-27 | — | — | US | claimed |
| US-6977256-B2 | Compounds and compositions as cathepsin S inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-20 | — | — | US | claimed |
| US-20050267044-A1 | Novel compounds and compositions as cathepsin S inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-01 | — | — | US | claimed |
| US-6900237-B2 | Sulfonamide compounds as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2005-05-31 | — | — | US | claimed |
| US-20040192742-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. | 2004-09-30 | — | — | US | claimed |
| EP-0262919-B1 | PREPARATION OF ARYL CARBONYL COMPOUNDS | RAYCHEM LIMITED (GB) | 1991-09-11 | — | — | EP | claimed |
| EP-0124276-B1 | PREPARATION OF AROMATIC POLYMERS | RAYCHEM CORPORATION (a Delaware corporation) (US) | 1989-03-22 | — | — | EP | claimed |
| EP-0069597-B1 | PREPARING P-PHENOXY-BENZOYL COMPOUNDS | RAYCHEM CORPORATION (a California corporation) (US) | 1984-10-10 | — | — | EP | claimed |
| US-4474990-A | Preparing p-phenoxy benzoyl compounds | RAYCHEM CORPORATION (US) | 1984-10-02 | — | — | US | claimed |
| EP-0060943-B1 | PARAPHENOXYBENZOTRICHLORIDE, ITS PREPARATION AND USE | OCCIDENTAL CHEMICAL CORPORATION (US) | 1984-06-13 | — | — | EP | claimed |
| EP-0069597-A1 | Preparing p-phenoxy-benzoyl compounds | RAYCHEM CORPORATION (a California corporation) (US) | 1983-01-12 | — | — | EP | claimed |
| US-4308161-A | FOR UPGRADING BLACK COLOR OF BLACK LIQUID CRYSTAL DISPLAYS | GENERAL ELECTRIC COMPANY (US) | 1981-12-29 | — | — | US | claimed |
| US-4308164-A | Novel yellow azo dyes and dichroic liquid crystal composition made therewith | GENERAL ELECTRIC COMPANY (US) | 1981-12-29 | — | — | US | claimed |
| US-4308163-A | IMPROVING BLACK COLOR OF DICHROIC DYES | GENERAL ELECTRIC COMPANY (US) | 1981-12-29 | — | — | US | claimed |
| US-4198205-A | SULFONIC ACID-FREE DISPERSE DYES | BASF AKTIENGESELLSCHAFT (DE) | 1980-04-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267044-A1 | Novel compounds and compositions as cathepsin S inhibitors | CTSS, CTSB, CTSE | LTA4H 919/4885TSHR 4383/4885NR1H2 2799/4885 |
| US-20070203138-A1 | Novel Compounds and Compositions as Cathepsin S Inhibitors | CTSS, CTSB, CTSE | LTA4H 919/4885TSHR 4383/4885NR1H2 2799/4885 |
| US-20040192742-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSS, CTSB, CTSE | LTA4H 736/4885TSHR 4285/4885NR1H2 2824/4885 |
| US-20070135386-A1 | Novel Compounds and Compositions as Cathepsin Inhibitors | CTSS, CTSB, CTSE | LTA4H 736/4885TSHR 4285/4885NR1H2 2824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.